Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study

BACKGROUND: Teriflunomide is a once-daily oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (MS). We aimed to obtain data on the effectiveness, tolerability, and subject satisfaction with teriflunomide (Aubagio®) under clinical practice conditions in un...

Descripción completa

Detalles Bibliográficos
Autores principales: Kallmann, Boris A., Tiel-Wilck, Klaus, Kullmann, Jennifer S., Engelmann, Ulrich, Chan, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437319/
https://www.ncbi.nlm.nih.gov/pubmed/30944584
http://dx.doi.org/10.1177/1756286419835077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437319/
https://www.ncbi.nlm.nih.gov/pubmed/30944584
http://dx.doi.org/10.1177/1756286419835077

Ejemplares similares